VTRS
Viatris Inc Health Care Pharmaceutical Preparations S&P 500Russell 3000
$19.04Close
$23.7BMarket cap
$9.76 – $19.2052-week range
Nov 5, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 89 · stronger than 89% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high 1% below its 52-week high
Cautions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
1%
1wk
up 5.8%
price change
1mo
up 7.4%
price change
12-month return
up 90%
market up 11% ·
its own up 81%
F-score
—
— Not assessed
Altman Z
0.85
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.6×
price / book
Earnings yield
down 7.6%
EBIT / enterprise value
Cheaper than
57%
of the market · around average
Revenue growth
down 3%
year on year
EPS growth
—
latest quarter
Sales growth
up 5%
latest quarter · -3 pts
ROE
down 21%
return on equity
Free cash margin
up 14%
$1.9B FCF
D/E
0.85
long-term debt / equity
Net debt / EBITDA
82.5×
Interest cover
Lossoperating loss
Piotroski tests
Repair signals
- Long-term debt down 11% ($14.0B → $12.5B)
Trade setup
ATR%
2.5%
$0.48 a day · 2×ATR $18.07
RS
89 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.31
50 sessions
Implied move
8.7%
by Nov 20, 2026 · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Heavily indebted Net debt is 82.5 times EBITDA — roughly 83 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Gross margin narrowing Gross margin fell from 38.3% to 35.2%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 3.0% over the year, from $14.7B to $14.3B.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026-7% vs market2 sessions after results
Options
$75,69536.7% IV · activity
Financials
- Gross 35%
- Net -25%
- Free cash 14%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.8B | $17.8B | $16.2B | $15.4B | $14.7B | $14.3B |
| Gross margin | 32% | 31% | 40% | 42% | 38% | 35% |
| Operating income | -$210.8M | -$34.0M | $1.6B | $766.2M | $10.1M | -$2.7B |
| Net income | -$669.9M | -$1.3B | $2.1B | $54.7M | -$634.2M | -$3.5B |
| Net margin | -6% | -7% | 13% | 0% | -4% | -25% |
| Earnings per share | -$1.11 | -$1.05 | $1.71 | $0.05 | — | — |
| Free cash flow | $988.8M | $2.6B | $2.6B | $2.5B | $2.0B | $1.9B |
| Free cash margin | 8% | 14% | 16% | 16% | 13% | 14% |
| Cash | $844.4M | $701.2M | $1.3B | $991.9M | $734.8M | $1.3B |
| Long-term debt | $22.4B | $19.7B | $18.0B | $16.2B | $14.0B | $12.5B |
| Shareholders' equity | $23.0B | $20.5B | $21.1B | $20.5B | $18.6B | $14.7B |
| Shares outstanding | — | — | — | — | — | 1.25bn |
Next report
Nov 5, 2026 · before the open
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±8.7%
$17 – $21 by Nov 20, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±7.0%
last 4: -6.9% · +7.6% · -7.2% · -5.9%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
1.2× the usual move
What options price now
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 36.7% priced · 27.9% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $75,695 calls $65,942 · puts $9,752 · latest session
- 0.15× +0.08 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +6.88k · puts +1.14k past week
For options traders: ATM IV 36.7% (+2.0% 1w) · 1m ÷ 3m IV 1.14 · 25Δ skew 2.7 pts · Net GEX $1.2M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 8, 2026 | Material agreement · Other events ↗ |
| Aug 6, 2026 | Results · Other events ↗ |
| Jul 1, 2026 | Material agreement · New obligation ↗ |
| Jun 18, 2026 | Material agreement · New obligation ↗ |
| Jun 15, 2026 | Other events ↗ |
| May 15, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results · Other events ↗ |
| May 4, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 26, 2026 | Results · Restructuring · Other events ↗ |
| Feb 3, 2026 | Director or officer change ↗ |
| Dec 8, 2025 | Regulation FD ↗ |
| Dec 5, 2025 | Shareholder vote ↗ |